Unicycive Therapeutics, Inc. UNCY PHARMA
Company Overview
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +14.06% |
| 6 Months: | -28.65% |
| 3 Months: | -24.47% |
| 1 Month: | -0.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 41.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UNCY Unicycive Therapeutics, Inc. PHARMA | 5.03 | -2.87 | $137.79M | 0.00% | -97.75% | -101.07% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 951.00K | 675.00K | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.99M | 6.96M | 7.34M | 7.22M | 8.44M |
| Operating Income | -336.00K | -626.00K | -731.00K | -779.00K | -4.71M | -3.54M | -3.64M | -5.55M | -4.20M | -4.32M | -5.94M | -9.20M | -7.40M | -6.25M | - | -7.99M | -6.96M | -7.34M | -7.22M | -8.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 720.00K | -6.30M | -5.85M | -14.49M | -12.61M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.00K | 13.00K | 15.00K | 27.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 570.00K | -6.45M | -6.01M | -14.67M | -12.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -338.00K | -702.00K | -964.00K | -1.10M | -5.20M | -3.54M | -3.64M | -5.56M | -14.57M | -3.84M | -4.33M | -20.96M | 9.86M | -4.10M | - | 570.00K | -6.45M | -6.01M | -14.67M | -12.82M |
| Diluted EPS | - | - | -0.11 | -0.13 | -0.37 | -0.24 | -0.24 | -0.37 | -0.97 | -0.29 | -0.13 | -0.61 | -1.50 | -0.46 | - | -0.50 | -0.52 | -0.33 | - | -0.54 |
| R&D Expense | 182.00K | 304.00K | 450.00K | 493.00K | 3.78M | 1.93M | 1.86M | 4.80M | 3.03M | 2.27M | 3.37M | 6.81M | 4.87M | 3.04M | - | 2.17M | 1.75M | 2.96M | - | 1.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 951.00K | 675.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 19.00M | 21.45M | 32.12M | 29.52M |
| Operating Income | -2.02M | - | -18.05M | -20.77M | -32.12M | -29.52M |
| EBITDA | - | - | -17.89M | -30.18M | -36.23M | -25.91M |
| Interest Expense | - | - | 6.00K | 82.00K | 71.00K | 71.00K |
| Pretax Income | - | - | -18.06M | -30.54M | -36.73M | -26.55M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -2.26M | - | -18.06M | -30.54M | -36.73M | -26.55M |
| Diluted EPS | - | - | -12.00 | -12.80 | -5.65 | -1.67 |
| R&D Expense | 1.01M | 6.08M | 12.44M | 12.90M | 20.01M | 9.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 204.00K | - | 2.82M | 14.19M | 31.67M | 49.13M |
| Current Assets | - | - | - | 2.64M | 13.40M | 30.95M | 48.96M |
| Cash & Equivalents | - | - | - | 455.00K | 9.70M | 26.14M | 29.20M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.88M | - | 3.28M | 18.00M | 24.24M | 18.94M |
| Current Liabilities | - | 2.88M | - | 3.28M | 17.53M | 24.12M | 18.94M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 201.00K | 811.00K | 773.00K | 199.00K |
| Total Equity | -884.00K | -2.67M | - | -466.00K | -3.81M | 7.43M | 30.20M |
| Shares Outstanding | - | - | - | 1.52M | 3.48M | 11.38M | 22.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.46M | - | -15.65M | -18.28M | -28.57M | -31.32M |
| Investing Cash Flow | - | - | -2.00K | -12.00K | -72.00K | -12.10M |
| Financing Cash Flow | 1.44M | - | -471.00K | 27.54M | 45.09M | 46.47M |
| Capital Expenditure | - | - | -2.00K | -12.00K | -72.00K | -24.00K |
| Free Cash Flow | - | - | -15.65M | -18.30M | -28.65M | -31.34M |
| Net Change in Cash | - | - | -16.12M | 9.25M | 16.44M | 3.06M |
| Dividends Paid | - | - | - | 900.00K | 1.09M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,898.2% | -3,077.6% | - | - |
| Net Margin % | - | - | -1,898.8% | -4,525.0% | - | - |
| ROE % | 84.8% | - | 3,875.1% | 801.9% | -494.3% | -87.9% |
| ROCE % | 75.6% | - | 3,873.8% | 621.4% | -425.5% | -97.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.07% | 1.41M | $6.78M |
| 2 | Nantahala Capital Management, LLC | 5.03% | 1.40M | $6.73M |
| 3 | Vanguard Capital Management LLC | 3.85% | 1.07M | $5.14M |
| 4 | Octagon Capital Advisors LP | 3.59% | 1.00M | $4.80M |
| 5 | Geode Capital Management, LLC | 2.02% | 564.02K | $2.71M |
| 6 | Marshall Wace LLP | 1.97% | 547.86K | $2.63M |
| 7 | Vivo Capital, LLC | 1.97% | 550.00K | $2.64M |
| 8 | Logos Global Management LP | 1.70% | 473.56K | $2.27M |
| 9 | State Street Corporation | 1.62% | 450.16K | $2.16M |
| 10 | Diametric Capital, Lp | 1.34% | 374.13K | $1.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UNCY
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxNT2RybkM4Q3RoVHNDYlI0Nm50SzFIY3FFajdZV2x3MjZMTlpjRXA2SEhYLTFoS1VWV0pOSkVfM21JTU9lRVJSQ0lmdWs2QWlNWGFHLXJzZUdCS3ItN1dybnVsR2lSWmVRNE5kMG5aVzZzckwxaHVRTUlxMGJ3NTkyR3BJR29hUFFXOVF6X1…
UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc. - Morningstar
<a href="https://news.google.com/rss/articles/CBMirAJBVV95cUxPc2dmcnRSV3ozalpod0NReFgwUV9UMVh6a0M1RnMtUzhWWWVreENjZE5vbjJyZDF5dXc5Q2paekRITEJjWHkzNVBLVUdFbEdoNXdxQUhnVGFiZVlQLUdWYUxDV3VQNXpNQnlZZVVLajBNVkVWQlRCNUdNcUtETHdDMmNRN0Z1RG9mdXhlek…
(UNCY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNTHlNcU1wSVl1T1ZoOUM5V21kbGxkaGcxeWJ2OEZUZ1pPZHlpVVJveHNrbi1UcmlVX2RVZUtGcDZEQm9ta2ZDc2xkVHJ0dGhwb1MxMS1nWi1QakYzSFIzTU0tWEkxTjh1YUIzODlKY0g1RE1qNWVSZlJ4b0c1bWxlR3BjbTk5cHAzRkRBTn…
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPU3hLQ3VvZUhHSUlkTXVpWXVGTjRjcUM3c0ZyWEhFR0JJb3ZLdk9KMHFxb3hUc0tqMWNicDlUREpkZWJFMnNUNTB6aGt6M0NyUlBrNWF3TkpCSF9CVk5SNjU0c1hZWmd0TlhuUFVnandDS1ZCTGI0ZTRMUUNxNFVxY08wZXFzTXZ2dnA4ST…
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNaXJJMFVWaHhLdDEzNnFERlhVek9pUl9lVWlnUFBtb0phTVQ0ODhIUTBabW5RTmJLZjI3NS0yMTdHT1VWd0JiTTk3SGREN3RDQ2RiaFpYbzMyampQUWtZVHBzNW0waVBvcll5UFc0RmxjaE9xM3RBZFZia0VNY0ZabjdhajgtbXNKN0xwZ2…
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPaWdCblRpeVlXMC1neXVnUmMyQ3ZIbHpKZW9EanBKTXlMVE9Wc2E2a3dLSWlvRS1pZURZMnhqdXpjTnRrMHg4b1dyblVWNlVRWGkwc2h5SU0xVklGOERxMDE4RDNZekNERXdxZGlNakdIN2NjSDRFZTVNblpTRVVzaGx5b19pR1Z5c2NVcn…
UNCY — Frequently Asked Questions
What is the current share price of Unicycive Therapeutics, Inc. (UNCY)?
As of 2026-09-19 21:16 PDT, Unicycive Therapeutics, Inc. (UNCY) trades at $5.03 on NasdaqCM. Its 52-week range is $3.74 to $8.56.
What is the market capitalisation of UNCY?
Unicycive Therapeutics, Inc. (UNCY) has a market capitalisation of $137.79M on NasdaqCM.
What is the P/E ratio of UNCY?
UNCY trades at a trailing price-to-earnings (P/E) ratio of -2.87. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.51.
What is the return on equity (ROE) of UNCY?
UNCY has a return on equity (ROE) of -101.07%. Its return on capital employed (ROCE) is -97.75%.
Is UNCY a good stock to buy?
This page provides a data-driven analysis of Unicycive Therapeutics, Inc. (UNCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.